Precigen Inc (PGEN) Expected Move

Tracking the PGEN expected move helps you see how far Precigen Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Precigen Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the PGEN expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For PGEN, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The PGEN expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Precigen Inc is unlikely to go.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L.

lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the PGEN expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Precigen Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about PGEN.